Abstract

BackgroundUse of chemotherapeutic drugs in advanced age geriatric cancer patients is associated with increased treatment related morbidity, one major neurological complication being peripheral neuropathy is one of major disabling morbidity expected in geriatric population due to poor nutrition status and significant co-morbidities. Our study aims to assess the incidence and severity of chemotherapy induced peripheral neuropathy in geriatric patients with help of CIPN tools when compared to younger patients on chemotherapy. MethodsA prospective observational study was conducted in medical oncology wards of tertiary care hospital, Bangalore. Subjects with histological confirmed malignancies who had received planned chemotherapy were recruited in this study. All patients underwent a detailed clinical evaluation for screening CIPN at 3rd cycle of chemotherapy, 6th cycle, follow up to 3 months after cessation by using activity daily living screening tool (eviQ tool), to assess the incidence and severity of symptoms of peripheral neuropathy with objective gradation according to CTCAE V 4.3. Subjects in the study were divided into two groups to those younger than 60 years (group I, n = 63) and those elder or equal to 60 years (group II, n = 32). The incidence and severity of chemotherapy induced peripheral neuropathy in two groups were assessed by screening tools and clinical evaluation. ResultsThe incidence of CIPN was more in group II (16/32,IR=50%), (p = 0.282) than group 1 (26/63,IR=44.4%), (p= -0.053). Similarly, according to the CTCAE V4.3 grading, the severity of CIPN was more in group II (p = 0.400) than group I (p = -0.145). The between age groups comparison revealed that there is significant association between increased incidence and severity of CIPN in geriatric patients. ConclusionsGeriatric patients have greater risk for developing chemotherapy induced peripheral neuropathy (CIPN) when compared to younger use. Adequate use of supportive care would make the reduction in adverse effects, reduce treatment failures, thus allows adequate dosing of drugs and will improve quality of life. Legal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.